About Daniel Sem, Ph.D., MBA, JD

Daniel Sem, Ph.D., MBA, JD is a Professor and the Dean of the Batterman School of Business and a Professor of Pharmaceutical Sciences at Concordia University Wisconsin. He is also the CEO of both Bridge to Cures, Inc. and Retham Technologies, Co-Founder and Vice President for Business Development of Estrigenix Therapeutics and has been the Director of the Remedium eXchange (Rx) Think Tank since June 2017. He co-founded Triad Therapeutics which ranked in the top 10 biotech startups in the U.S. by Drug Discovery Today and was later acquired by Novartis for $60 million.

Dan received his Bachelor of Science degree in chemistry from the University of Wisconsin-Milwaukee, his Ph.D. in biochemistry from the University of Wisconsin-Madison and his Juris Doctor and Master of Business Administration degrees from Marquette University. He joined the faculty at Marquette University in 2002 and served as an Assistant then Associate Professor of Organic Chemistry before joining Concordia University’s new School of Pharmacy in 2011, transitioning to his current position as Dean of Business in July of 2015.

Dan has published more than 70 peer-reviewed papers and has 10 issued patents, studying protein interactions using various biophysical techniques, including NMR, fluorescence spectroscopy, mechanistic enzymology, chemical biology and computational methods (e.g. docking; cheminformatics). His research goals are to combine his business, scientific and legal expertise to develop and help others develop new ways to treat human disease, and – more broadly – improve the human condition through innovation and entrepreneurship.

With over 25 years of experience as a healthcare entrepreneur, with startups in both industry and academics, Dan works extensively with universities, industries and government in southeast Wisconsin to build shared drug development and commercialization resources for the region.